Literature DB >> 16271723

A strategy of retrograde injection of bone marrow mononuclear cells into the myocardium for the treatment of ischemic heart disease.

Shin-Ichiro Yokoyama1, Noboru Fukuda, Yuxin Li, Kazuhiro Hagikura, Tadateru Takayama, Satoshi Kunimoto, Junko Honye, Satoshi Saito, Mika Wada, Aya Satomi, Maiko Kato, Hideo Mugishima, Yoshiaki Kusumi, Masako Mitsumata, Toyoaki Murohara.   

Abstract

OBJECTIVE: Bone marrow cells implantation (BMI) has been reported to efficiently improve ischemic heart disease. However, BMI strategies are generally invasive. To establish a BMI strategy for ischemic heart disease, we performed implantation of autologous cryopreserved mononuclear cells (MNCs) from bone marrow (BM) retrogradely into the myocardium via the coronary vein in pigs with acute myocardial infarction (AMI) and old myocardial infarction (OMI).
METHODS: BM cells were harvested from the pigs' fumurs. MNCs were collected by centrifugation and were cryopreserved. Anterior myocardial infarction was induced by occlusion of the midportion of the left anterior descending coronary artery without surgical intervention. Frozen BM cells were quickly thawed and injected retrogradely via the coronary vein into the myocardium through a single balloon infusion catheter 6 h and 2 weeks after the induction of infarction. Four weeks after implantation, coronary arteriograms were obtained, cardiac function was analyzed with the use of a conductance catheter, and histopathologic analysis was performed with a confocal laser microscope. Plasma levels of natriuretic peptides and angiogenic growth factors were measured after BMI.
RESULTS: Flow cytometric analysis revealed that 90% of cryopreserved BM cells were viable in vitro. Labeled BM cells were entirely distributed around in the infarcted area of maycardium in pigs. BMI increased collateral neovascuralization in infarcted hearts. BMI significantly improved cardiac function in AMI with BMI and OMI with BMI groups. BMI also increased the formation of microcapillary arteries in infarcted hearts. Levels of natriuretic peptides were significantly decreased, and levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF2) were significantly increased after BMI. Confocal laser microscopy revealed the presence of proliferative and activated myocardial cells in infarcted hearts after BMI.
CONCLUSION: The retrograde infusion of cryopreserved BM cells into myocardium efficiently induced angiogenesis and improved cardiac function in pigs with AMI or OMI. These results suggest that the present strategy of BMI will be safe and feasible as an angiogenic cell therapy for ischemic heart disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16271723     DOI: 10.1016/j.yjmcc.2005.06.008

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  15 in total

1.  Cardiac function in dogs with chronic Chagas cardiomyopathy undergoing autologous stem cell transplantation into the coronary arteries.

Authors:  Marlos G Sousa; Daniel Paulino-Junior; João P E Pascon; Gláucia B Pereira-Neto; Roberta Carareto; Tatiana Champion; Aparecido A Camacho
Journal:  Can Vet J       Date:  2011-08       Impact factor: 1.008

Review 2.  Cell therapy for the treatment of coronary heart disease: a critical appraisal.

Authors:  Kai C Wollert; Helmut Drexler
Journal:  Nat Rev Cardiol       Date:  2010-02-23       Impact factor: 32.419

Review 3.  Human coronary venous anatomy: implications for interventions.

Authors:  Julianne H Spencer; Sara E Anderson; Paul A Iaizzo
Journal:  J Cardiovasc Transl Res       Date:  2013-01-11       Impact factor: 4.132

Review 4.  Bone marrow cell injection for chronic myocardial ischemia: the past and the future.

Authors:  Jan van Ramshorst; Sander F Rodrigo; Martin J Schalij; Saskia L M A Beeres; Jeroen J Bax; Douwe E Atsma
Journal:  J Cardiovasc Transl Res       Date:  2011-01-07       Impact factor: 4.132

Review 5.  Non-surgical stem cell delivery strategies and in vivo cell tracking to injured myocardium.

Authors:  Tycho I G van der Spoel; Joe Chun-Tsu Lee; Krijn Vrijsen; Joost P G Sluijter; Maarten Jan M Cramer; Pieter A Doevendans; Eric van Belle; Steven A J Chamuleau
Journal:  Int J Cardiovasc Imaging       Date:  2010-06-25       Impact factor: 2.357

6.  Magnetic targeting enhances retrograde cell retention in a rat model of myocardial infarction.

Authors:  Zheyong Huang; Yunli Shen; Aijun Sun; Gangyong Huang; Hongmin Zhu; Bingqing Huang; Jianfeng Xu; Yanan Song; Ning Pei; Jing Ma; Xiangdong Yang; Yunzeng Zou; Juying Qian; Junbo Ge
Journal:  Stem Cell Res Ther       Date:  2013       Impact factor: 6.832

7.  Cell tracking and therapy evaluation of bone marrow monocytes and stromal cells using SPECT and CMR in a canine model of myocardial infarction.

Authors:  Gerald Wisenberg; Katie Lekx; Pam Zabel; Huafu Kong; Rupinder Mann; Peter R Zeman; Sudip Datta; Caroline N Culshaw; Peter Merrifield; Yves Bureau; Glenn Wells; Jane Sykes; Frank S Prato
Journal:  J Cardiovasc Magn Reson       Date:  2009-04-27       Impact factor: 5.364

Review 8.  Current stem cell delivery methods for myocardial repair.

Authors:  Calvin C Sheng; Li Zhou; Jijun Hao
Journal:  Biomed Res Int       Date:  2012-12-27       Impact factor: 3.411

9.  Concomitant Retrograde Coronary Venous Infusion of Basic Fibroblast Growth Factor Enhances Engraftment and Differentiation of Bone Marrow Mesenchymal Stem Cells for Cardiac Repair after Myocardial Infarction.

Authors:  Xiao Wang; Lei Zhen; Huangtai Miao; Qiwei Sun; Ya Yang; Bin Que; Edmundo Patricio Lopes Lao; Xingxin Wu; Hongmei Ren; Shutian Shi; Wayne B Lau; Xinliang Ma; Changsheng Ma; Shaoping Nie
Journal:  Theranostics       Date:  2015-06-08       Impact factor: 11.556

Review 10.  Mesenchymal Stem Cells for Cardiac Regenerative Therapy: Optimization of Cell Differentiation Strategy.

Authors:  Han Shen; Ying Wang; Zhiwei Zhang; Junjie Yang; Shijun Hu; Zhenya Shen
Journal:  Stem Cells Int       Date:  2015-08-03       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.